Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Fractyl Health, Inc. ( (GUTS) ) is now available.
On January 31, 2025, Fractyl Health, Inc. announced a strategic reprioritization to focus on its REMAIN-1 pivotal study, a trial for its lead product candidate, Revita, aimed at weight maintenance post-GLP-1 drug withdrawal due to strong patient and physician demand. The company is advancing its Rejuva gene therapy platform into first-in-human studies and pausing investment in other Revita programs, resulting in a workforce reduction of 22 employees. This strategic shift is expected to extend Fractyl’s cash runway into 2026 and reflects the company’s focus on addressing critical gaps in obesity treatment.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a metabolic therapeutics company based in Burlington, MA, focusing on pioneering treatments for obesity and type 2 diabetes (T2D). The company’s lead product candidate, Revita, aims to remodel the duodenal lining to reverse damage caused by chronic high-fat and high-sugar diets, while their Rejuva platform is developing novel gene therapies targeting the pancreas.
YTD Price Performance: -8.92%
Average Trading Volume: 337,538
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $93.31M
See more insights into GUTS stock on TipRanks’ Stock Analysis page.
